BD Diagnostics said it received clearance from the FDA for the BD GeneOhm StaphSR assay, which the company says is the first test to rapidly and simultaneously identify two deadly healthcare-associated infections (HAIs) - Staphylococcus aureus and Methicillin-resistant Staphylococcus aureus (MRSA) - from patients with positive blood cultures.
